GSK (GSK) Stock Forecast & Price Target

Q: What analysts cover GSK?

GSK has been rated by research analysts at Berenberg Bank , Deutsche Bank Aktiengesellschaft , Jefferies Financial Group , and Royal Bank Of Canada in the past 90 days.

GBX 1,894 -20.00 (-1.04%)

As of 10/23/2026 12:13 PM Eastern

Compare

GSK - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 8 Analyst Ratings

Sell
1

Hold
5

Buy
2

Based on 8 Wall Street analysts who have issued ratings for GSK in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 1 has given a sell rating, 5 have given a hold rating, and 2 have given a buy rating for GSK.

Consensus Price Target

GBX 2,064.38

According to the 8 analysts' twelve-month price targets for GSK, the average price target is GBX 2,064.38. The highest price target for GSK is GBX 2,500, while the lowest price target for GSK is GBX 1,500. The average price target represents a forecasted upside of 9.00% from the current price of GBX 1,894.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for GSK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for GSK and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GSK Analyst Ratings Over Time

Type	Current Forecast 10/24/25 to 10/24/26	1 Month Ago 9/24/25 to 9/24/26	3 Months Ago 7/26/25 to 7/26/26	1 Year Ago 10/24/24 to 10/24/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	1 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	GBX 2,064.38	GBX 2,064.38	GBX 2,034.29	GBX 1,637.50
Consensus Rating	Hold	Hold	Hold	Hold

GSK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GSK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

GSK Stock vs. The Competition

Type	GSK	Healthcare Companies
Consensus Rating Score	2.13	2.32
Consensus Rating	Hold	Hold
News Sentiment Rating	Positive News See Recent GSK News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Action	Rating	Price Target	Report Date Upside/Downside
10/20/2026	Jefferies Financial Group 3 of 5 stars	Reiterated Rating	Buy	GBX 2,500	+34.34%
9/29/2026	Deutsche Bank Aktiengesellschaft 3 of 5 stars	Reiterated Rating	Hold	GBX 2,000	+7.50%
9/15/2026	Berenberg Bank 2 of 5 stars	Boost Target	Hold	GBX 2,000 ➝ GBX 2,200	+18.38%
9/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sector perform	GBX 1,975	+9.57%
5/6/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Target	Neutral	GBX 2,250 ➝ GBX 2,100	+12.06%
3/25/2026	Shore Capital Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
1/23/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral	GBX 1,940	+7.51%
1/7/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Underweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:46 PM ET.

Should I Buy GSK Stock? GSK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 23, 2026. Please send any questions or comments about these GSK pros and cons to contact@marketbeat.com.

GSK
Bull Case

Here are some ways that investors could benefit from investing in GSK plc:

GSK plc recently secured FDA approval for Hibsago, a novel hepatitis B drug that offers a potential functional cure, marking a significant breakthrough in the company's oncology and infectious disease pipeline that could drive future revenue growth.
The company has demonstrated strong financial performance with a return on equity of 28.35% and a net margin of 14.52% in its latest quarterly results, indicating efficient capital management and profitability that supports shareholder value.
Investors can benefit from a stable dividend yield of 3.64%, which provides a consistent income stream and reflects the company's commitment to returning cash to shareholders despite its ongoing research and development investments.
GSK plc has expanded its oncology portfolio by securing ex-China rights to a KRAS EGFR cancer drug through a strategic partnership, positioning the company to capture market share in targeted cancer therapies with high unmet medical needs.
The stock currently trades at $1894.00, which is below the consensus price target of GBX 2,064.38, suggesting potential upside for investors as analysts maintain a Hold consensus with several Buy ratings from firms like Jefferies Financial Group.

GSK
Bear Case

Investors should be bearish about investing in GSK plc for these reasons:

The company carries a high debt-to-equity ratio of 103.36, which indicates significant leverage and could limit financial flexibility or increase interest expenses, posing a risk to earnings stability in a rising interest rate environment.
GSK plc has a current ratio of 0.82 and a quick ratio of 0.73, both below 1.0, suggesting that the company may face short-term liquidity challenges as its current liabilities exceed its current assets, potentially impacting its ability to meet immediate obligations.
The stock has experienced a recent decline of 1.0% to $1894.00, and trading volume of 6,173,946 shares is significantly lower than the average volume of 12,407,307, indicating reduced market interest or potential selling pressure that could affect price stability.
Despite recent approvals, the company's profit has fallen in the latest period, as noted in recent financial reports, which may signal operational challenges or increased costs that could erode margins and impact future earnings growth.
The consensus rating from analysts is Hold, with five Hold ratings and one Sell rating outweighing the two Buy ratings, reflecting a cautious outlook from the investment community that may limit near-term price appreciation potential.

GSK Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for GSK is GBX 2,064.38, with a high forecast of GBX 2,500 and a low forecast of GBX 1,500.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There is currently 1 sell rating, 5 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.

According to analysts, GSK's stock has a predicted upside of 9.00% based on their 12-month stock forecasts.

GSK has been rated by research analysts at Berenberg Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, and Royal Bank Of Canada in the past 90 days.

Analysts like GSK less than other "healthcare" companies. The consensus rating score for GSK is 2.13 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how GSK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With GSK Recommendations

MarketBeat monitors more than a dozen sources for GSK analyst ratings, with the most recent rating issued on 10/20/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Stock Forecast & Price Target